Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis

Journal of Proteome Research

Volumn 8, Issue 1, 2009, Pages 362-373

  Bouchal, Pavel ^a,b   Roumeliotis, Theodoras ^c   Hrstka, Roman ^a   Nenutil, Rudolf ^a   Vojtesek, Borivoj ^a   Garbis, Spiros D ^c  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Biomarkers; Breast cancer; ITRAQ; Liquid chromatography; Mass spectrometry; Proteomics

Indexed keywords

BINDING PROTEIN; BIOLOGICAL MARKER; HEME; INTERFERON; STABLE ISOTOPE; CATION; INORGANIC SALT; PROTEOME; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER TISSUE; CONTROLLED STUDY; DISEASE SEVERITY; ELECTROSPRAY; ENERGY METABOLISM; HUMAN; HUMAN TISSUE; INTERFERON INDUCTION; ISOBARIC STABLE ISOTOPE TAGS AND TWO DIMENSIONAL LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; LYMPH NODE METASTASIS; NUCLEOTIDE SEQUENCE; PILOT STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; REGULATORY MECHANISM; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; TUMOR BIOPSY; VALIDATION STUDY; BIOPSY; BREAST TUMOR; CANCER DIAGNOSIS; CHEMISTRY; ION EXCHANGE CHROMATOGRAPHY; METABOLISM; METASTASIS; METHODOLOGY; MOLECULAR WEIGHT;

BIOPSY; BREAST NEOPLASMS; CATIONS; CHROMATOGRAPHY, ION EXCHANGE; CHROMATOGRAPHY, LIQUID; EARLY DETECTION OF CANCER; HUMANS; LYMPHATIC METASTASIS; MOLECULAR WEIGHT; NEOPLASM METASTASIS; PROTEOME; PROTEOMICS; SALTS; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 60849093488     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr800622b     Document Type: Article

References (48)

1. Greene, F. L.; Page, D. L.; Fleming, I. D.; Fritz, A.; Balch, C. M.; Haller, D. G.; Morrow M. AJCC Cancer Staging Manual, 6th ed.; Springer: New York, 2002.
2. Harris, L.; Fritsche, H.; Mennel, R.; Norton, L.; Ravdin, P.; Taube, S.; Somerfield, M. R.; Hayes, D. F.; Bast, R. C., Jr. American Society of Clinical Oncology American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007, 25, 5287-5312.
3. Goldhirsch, A.; Wood, W. C.; Gelber, R. D.; Coates, A. S.; Thurlimann, B.; Senn, H. J. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J. Clin. Oncol. 2003, 21, 3357-65.
4. Hondermarck, H.; Tastet, C.; Yazidi-Belkoura, I-E.; Toillon, R.-A.; Le Bourhis, X. Proteomics of breast cancer: The quest for markers and therapeutic targets. J. Proteome Res. 2008, 7, 1403-1411.
5. zhilov, I. V.; Seymour, S. L.; Patel, A. A.; Loboda, A.; Tang, W. H.; Keating, S. P.; Hunter, C. L.; Nuwaysir, L. M.; Schaeffer, D. A. The paragon algorithm: a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol Cell Proteomics 2007, 6, 1638-1655.
6. Camon, E.; Barrell, D.; Lee, V.; Dimmer, E.; Apweiler, R. The gene ontology annotation (GOA) database-an integrated resource of GO annotations to the UniProt knowledgebase. In Silico Biol. 2004, 4, 5-6.
7. De Souza, L.; Diehl, G.; Rodrigues, M. J.; Guo, J.; Romaschin, A. D.; Colgan, T. J.; Siu, K. W. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J. Proteome Res. 2005, 4, 377-386.
8. De Souza, L. V.; Grigull, J.; Ghanny, S.; Dubé, V.; Romaschin, A. D.; Colgan, T. J.; Siu, K. W. Endometrial carcinoma biomarker discovery and verification using differentially tagged clinical samples with multidimensional liquid chromatography and tandemmass spectrometry. Mol. Cell. Proteomics 2007, 6, 1170-1182.
9. Garbis, S. D.; Tyritzis, S. I.; Roumeliotis, T.; Zerefos, P.; Giannopoulou, E. G.; Vlahou, A.; Kossida, S.; Diaz, J.; Vourekas, S.; Tamvakopoulos, C.; Pavlakis, K.; Sanoudou, D.; Constan-tinides, C. A. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J. Proteome Res. 2008, 7 (8), 3146-3158.
10. Nakawaga, T.; Huang, S. K.; Martinez, S. R.; Tran, A. R.; Elashoff, D.; Ye, X.; Turner, R. R.; Giuiliano, A. E.; Hoon, D. S. B. Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis. Cancer Res. 2006, 66, 11825-11830.
11. Ricolleau, G.; Charbonnel, C.; Lodé, R.; Loussouarn, D.; Joalland, M. P.; Bogumil, R.; Jourdain, S.; Minvielle, S.; Campone, M.; Deporte-Fety, R.; Campion, L.; Jézéquel, P. Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics 2006, 6, 1963-1975.
12. Li, D. Q.; Wang, L.; Fei, F.; Hou, Y. F.; Luo, J. M.; Zeng, R.; Wu, J.; Lu, J. S.; Di, G. H.; Ou, Z. L.; Xia, Q. C.; Shen, Z. Z.; Shao, Z. M. Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics 2006, 6, 3352-3368.
13. Selicharova, I.; Sanda, M.; Mladkova, J.; Ohri, S. S.; Vashishta, A.; Fusek, M.; Jiracek, J.; Vetvicka, V. 2-DE analysis of breast cancer cell lines 1833 and 4175 with distinct metastatic organ-specific potentials: comparison with parental cell line MDA-MB-231. Oncol. Rep. 2008, 19, 1237-1244.
14. Ross, P. L.; Huang, Y. N.; Marchese, J. N.; Williamson, B.; Parker, K.; Hattan, S.; Khainovski, N.; Pillai, S.; Dey, S.; Daniels, S.; Purkayastha, S.; Juhasz, P.; Martin, S.; Bartlet-Jones, M.; He, F.; Jacobson, A.; Pappin, D. J. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 2004, 3, 1154-1169.
15. Ralhan, R.; DeSouza, L. V.; Matta, A.; Chandra Tripathi, S.; Ghanny, S.; Datta Gupta, S.; Bahadur, S.; Siu, K. W. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ-labeling and multidimensional liquid chromatography and tandem mass spectrometry. Mol. Cell. Proteomics 2008, 7, 1162-1173.
16. Chen, Y.; Choong, L. Y.; Lin, Q.; Philp, R.; Wong, C. H.; Ang, B. K.; Tan, Y. L.; Loh, M. C.; Hew, C. L.; Shah, N.; Druker, B. J.; Chong, P. K.; Lim, Y. P. Differential expression of novel tyrosine kinase substrates during breast cancer development. Mol. Cell. Proteomics 2007, 6, 2072-2087.
17. Rafai, N.; Gillette, M. A.; Carr, S. A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 8, 971-983.
18. Mischak, H.; Apweiler, R.; Banks, R. E.; Conaway, M.; Coon, J; Dominiczak, A.; Ehrich, J. H. H.; Fliser, D.; Girolami, M.; Hermjakob, H.; Hochstrasser, D.; Jankowski, J.; Julian, B. A.; Kolch, W.; Massy, Z.A.; Neusuess, C; Novak, J.; Peter, K.; Rossing, K.; Schanstra, J.; Semmes, O. J.; Theoderescu, D.; Thongboonkerd, V.; Weissinger, E. M.; Van Eyk, J. E.; Yamamoto, T. Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin. Appl. 2007, 1, 148-156.
19. Kessel, D.; Chou, T. H. Tumor-localizing components of the porphyrin preparation hematoporphyrin derivative. Cancer Res. 1983, 43, 1994-1999.
20. White, D. L.; Li, D.; Nurgalieva, Z.; El-Serag, H. B. Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and metaanalysis. Am. J. Epidemiol. 2008, 167, 377-389.
21. Senjo, M.; Ishibashi, T.; Imai, Y. Purification and characterization of cytosolic liver protein facilitating heme transport into apo-cytochrome b5 from mitochondria. Evidence for identifying the heme transfer protein as belonging to a group of glutathione S-transferases. J. Biol. Chem. 1985, 260, 9191-9196.
22. Megnin, F.; Faustino, P. J.; Lyon, R. C; Lelkes, P. I.; Cohen, J. S. Studies on the mechanism of selective retention of porphyrins and metalloporphyrins by cancer cells. Biochim. Biophys. Acta 1987, 929, 173-181.
23. Berg, J.; Tymoczko, J.; Stryer, L. Biochemistry, 5th ed.; W H. Freeman and Company: New York, 2002.
24. Greenberg, A. S.; Egan, J. J.; Wek, S. A.; Garty, N. B.; Blanchette-Mackìe, E. J.; Londos, C. Perilipin, a major hormonally regulated adipocyte-specific phosphoprotein associated with the periphery of lipid storage droplets. J. Biol. Chem. 1991, 266, 11341-11346.
25. Tsitsiloni, O. E.; Stiakakis, J.; Koutselinis, A.; Gogas, J.; Marko- poulos, C.; Yialouris, P.; Bekris, S.; Panoussopoulos, D.; Kiortsis, V.; Voelter, W.; Haritos, A. A. Expression of alpha-thymosins in human tissues in normal and abnormal growth. Proc. Natl. Acad. Sci. U.S.A. 1992, 90, 9504-9507.
26. Vareli, K.; Tsolas, O.; Frangou-Lazaridis, M. Regulation of prothymosin alpha during the cell cycle. Eur. J. Biochem. 1996, 238, 799-806.
27. Martini, P. G.; Delage-Mourroux, R.; Kraichely, D. M.; Katzenel-lenbogen, B. S. Prothymosin alpha selectively enhances estrogen receptor transcriptional activity by interacting with a repressor of estrogen receptor activity. Mol. Cell. Biol. 2000, 20, 6224-6232.
28. Martini, P. G.; Katzenellenbogen, B. S. Regulation of prothymosin alpha gene expression by estrogen in estrogen receptor-containing breast cancer cells via upstream half-palindromic estrogen response element motifs. Endocrinology 2001, 142, 3493-3501.
29. Meijer, D.; van Agthoven, T.; Bosma, P. T.; Nooter, K.; Dorssers, L. C. Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells. Mol. Cancer Res. 2006, 4, 379-386.
30. Meijer, D.; Jansen, M. P.; Look, M. P.; Ruigrok-Ritstier, K.; van Staveren, I. L.; Sieuwerts, A. M.; van Agthoven, T.; Foekens, J. A.; Dorssers, L. C.; Berns, E. M.; TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer. Breast Cancer Res. Treat. 2008, in press.
31. Paun, A.; Pitha, P. M. The IRF family, revisited. Biochimie 2007, 89, 744-753.
32. Gresser, I. The antitumor effects of interferon: A personal history. Biochimie 2007, 89, 723-728.
33. Adam, P. J.; Boyd, R.; Tyson, K. L.; Fletcher, G. C.; Stamps, A.; Hudson, L.; Poyser, H. R.; Redpath, N.; Griffiths, M.; Steers, G.; Harris, A. L.; Patel, S.; Berry, J.; Loader, J. A.; Townsend, R. R.; Daviet, L.; Legrain, P.; Parekh, R.; Terrett, J. A. Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J. Biol. Chem. 2003, 278, 6482-6489.
34. Thompson, D. A.; Weigel, R. J. hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines. Biochem. Biophys. Res. Commun. 1998, 251, 111-116.
35. Pohler, E.; Craig, A. L.; Cotton, J.; Lawrie, L.; Dillon, J. F.; Ross, P.; Kernohan, N.; Hupp, T. R. The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol. Cell. Proteomics 2004, 3, 534-547.
36. Liu, D.; Rudland, P. S.; Sibson, D. R.; Platt-Higgins, A.; Barra-clough, R. Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res. 2005, 65, 3796-3805.
37. Wang, Z.; Hao, Y.; Lowe, A. W. The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res. 2008, 68, 492-497.
38. Kodama, J.; Hashimoto, I.; Seki, N.; Hongo, A.; Yoshinouchi, M.; Okuda, H.; Kudo, T. Thrombospondin-1 and -2 messenger RNA expression in invasive cervical cancer: correlation with angio-genesis and prognosis. Clin. Cancer Res. 2001, 7, 2826-2831.
39. Wu, M. P.; Tzeng, C. C.; Wu, L. W.; Huang, K. F.; Chou, C. Y. Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis. Cancer J. 2004, 10, 12-14.
40. Kaspar, M.; Zardi, L.; Neri, D. Fibronectin as target for tumor therapy. Int. J. Cancer 2006, 118, 1331-1339.
41. Dittmar, T. Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner. Clin. Exp. Metastasis 2008, 25, 11-32.
42. Borg, T. K.; Markwald, R. Periostin: more than just an adhesion molecule. Circ. Res. 2007, 3, 230-231.
43. Kudo, Y.; Siriwardena, B.S.M.S.; Hatano, H.; Ogawa, I.; Takata, T. Periostin: novel diagnostic and therapeutic target for cancer. Histol. Histopathol. 2007, 22, 1167-1174.
44. Puglisi, F.; Puppin, C.; Pegolo, E.; Andreetta, C.; Pascoletti, G.; D'Aurizio, F.; Pandolfl, M.; Fasola, G.; Piga, A.; Damante, G.; Di Loreto, C. Expression of periostin in human breast cancer. J. Clin. Pathol. 2008, 61, 494-498.
45. Hofler, H.; Luber, B. Cell Adhesion Markers. In Molecular Oncology of Breast Cancer, Ross, J. S., Hortobagyi, G. N., Eds.; Jones and Bartlett Publishers; Sudbury, MA, 2005; pp 313-321.
46. Mueller, M. M.; Fusenig, N. E. Friends of foes-bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer. 2004, 4, 839-849.
47. Joyce, J. A. Theraupeutic targeting of the tumour microenvi-ronment. Cancer Cell. 2005, 7, 513-520.
48. Albini, A.; Sporn, M. The tumour microenvironment as a target for chemoprevention. Nat. Rev. Cancer. 2007, 7, 139-147.